You are here

ATTR

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Yahoo/GlobeNewswire

clinical trials

Flag link:

AstraZeneca adds Latin America to Ionis ATTR partnership for $20M

AstraZeneca adds Latin America to Ionis ATTR partnership for $20M

Fierce Biotech

Ionis Pharmaceuticals

Flag link:

Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam

Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam

Fierce Biotech

Ionis Pharmaceuticals

Flag link:

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

Pharmaforum

Flag link:

Alnylam, awaiting key study data, builds case for its next rare disease drug

Alnylam, awaiting key study data, builds case for its next rare disease drug

BioPharma Dive

Flag link:

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

Pharmaforum

Flag link:

Pfizer's new Vyndaqel franchise worth far more than $1.5B, analyst figures

Pfizer's new Vyndaqel franchise worth far more than $1.5B, analyst figures

Fierce Pharma

Flag link:

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Motley Fool

Akcea Therapeutics

Eidos Therapeutics

Flag link:

Insurers Brace For Pfizer's $225K Heart Drug And Whether To Pay For It

Insurers Brace For Pfizer's $225K Heart Drug And Whether To Pay For It

Forbes

Flag link:

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

Xconomy

Flag link:

FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease

FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease

CP Wire

transthyretin amyloid cardiomyopathy

Flag link:

FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease

transthyretin amyloid cardiomyopathy

Flag link:

Eidos Therapeutics raises $106M IPO to advance ATTR med

Eidos Therapeutics raises $106M IPO to advance ATTR med

Fierce Biotech

Eidos Therapeutics

Flag link:

With Pfizer's 'pipeline surprise,' there's a new kid on the ATTR block

With Pfizer's 'pipeline surprise,' there's a new kid on the ATTR block

Fierce Pharma

Flag link:

Alnylam's star RNAi drug keeps the pace on the way to Phase III

Alnylam's star RNAi drug keeps the pace on the way to Phase III

Fierce Biotech

Flag link:

Alnylam's Biggest Opportunities

Alnylam's Biggest Opportunities

Motley Fool

Flag link: